Salt Lake-based Axial Biotech said Tuesday it has raised $15.3 million in a second financing round.

The round was led by new investor Johnson & Johnson Development Corp., with participation by existing investors vSpring Capital and Ohio Biotech Group LLC.

Axial said it would use the proceeds to accelerate its product development efforts and prepare for the launch of its scoliosis genetic test late next year.